Videos

The chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.

Neurology News Network for the week ending February 6, 2021.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided thoughts on why cognitive care and sleep disorder care should crossover more often.

The chief scientific officer of the Parkinson’s Foundation discussed strategies to close the gap between household income and telehealth use.

Episode 6 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and David G Standaert, MD, PhD, of University of Alabama at Birmingham. [WATCH TIME: 4 minutes]

The AASM board of directors member and professor of medicine at UCLA discussed some strengths of CBT.

The director of the Massachusetts General Hospital ALS Care Center spoke on the importance of data-based registries and how they can grow ALS research.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.

The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.

The director of the Massachusetts General Hospital ALS Care Center discussed the origins of ‘The Data is Here’ campaign and the reason to launch it now.

Neurology News Network for the week ending January 30, 2021.

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

The primary investigator of the phase 4 RESPOND study discussed the role that postmarketing studies can play in assessing treatments for SMA.

The clinical fellow at Massachusetts General Hospital gives his call to action on how what needs to change to improve EEG education among residency programs.

The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.